Clinical Trials Logo

Clinical Trial Summary

Diagnosis and treatment of tuberculosis are often delayed in hospitalized patients, leading to worse outcomes. Rapid diagnosis of tuberculosis currently relies on microscopy and molecular techniques, which have limitations including low sensitivity and high cost.Highly sensitive diagnostic technique is needed for more accurate rapid diagnosis of tuberculosis to aid earlier initiation of antituberculous therapy. Detection of Mycobacterium tuberculosis (MTB) antigens in the bloodstream can potentially allow early diagnosis of tuberculosis. This study aims to evaluate the diagnostic performance of a novel assay using nanotechnology to detect MTB antigens in patients admitted to hospital with suspected pulmonary and/or extrapulmonary tuberculosis. Blood will be taken from eligible patients, and will be sent to the School of Biological and Health Systems Engineering, Arizona State University, for detection of 10-kDa culture filtrate protein (CFP-10) and the 6 kDa early secretory antigenic target (ESAT-6), two antigens specific for MTB, using the Nanodisk-MS assay. Investigations, including microscopy, culture, MTB polymerase chain reaction (PCR), and imaging, will be performed for diagnosis of tuberculosis. The diagnostic performance of Nanodisk-mass spectrometry (MS) assay will be evaluated.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03271567
Study type Observational
Source Chinese University of Hong Kong
Contact
Status Completed
Phase
Start date September 28, 2017
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT06084715 - The INSTITUT Study
Terminated NCT03028129 - Prevention of Tuberculosis in Prisons Phase 4
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Withdrawn NCT03862248 - Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More Phase 3
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04919239 - Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB) Phase 2
Active, not recruiting NCT03251196 - TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
Recruiting NCT05926466 - BTZ-043 Dose Evaluation in Combination and Selection Phase 2
Recruiting NCT04752592 - Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Not yet recruiting NCT04968886 - TuBerculosis Viability Interregional Study and Agreement on Biological Tests
Not yet recruiting NCT04485156 - Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) Phase 3
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT01364324 - Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Active, not recruiting NCT04179500 - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers Phase 2
Completed NCT05899400 - A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
Recruiting NCT04938596 - Airborne Preventive Measures to Reduce New TB Infections in Household Contacts N/A
Recruiting NCT05455112 - Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis Phase 2
Completed NCT03044158 - GeneXpert Performance Evaluation for Linkage to Tuberculosis Care N/A
Withdrawn NCT03941496 - Azacytidine During Anti-tuberculosis Therapy Phase 1/Phase 2